Cell Therapies Forge Ahead In Japan with Reimbursement, Approval Decisions

A controversial cell therapy for spinal injuries receives coverage under Japan’s national health scheme, amid signs that the pricing of regenerative therapies may come under more scrutiny, while the first CAR-T treatment in the country takes a step closer to market.

T-cells attacking cancer_1200x675
Gains For New Cell Therapies In Japan • Source: Shutterstock

As expected following its approval in December, Japan has granted national insurance coverage to a pioneering, but somewhat controversial, cell therapy for the treatment of spinal cord injuries.

Meanwhile, Novartis AG’s Kymriah now looks set to become the first CAR-T therapy to be launched in the country...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia